share_log

Small Biotechs Are Pulling Public Offerings, IPOs Amid 'Current Market Conditions'

Small Biotechs Are Pulling Public Offerings, IPOs Amid 'Current Market Conditions'

小型生物科技在「當前市場狀況」下拉動公開募股，IPO
Benzinga Real-time News ·  2022/12/07 14:38
  • RNA biotech TransCode Therapeutics Inc (NASDAQ:RNAZ) withdrew its S-1 filing with the SEC that it made in late November.
  • TransCode said that the withdrawal reflects TransCode's belief that "current market conditions are not conducive for an offering on terms that would be in the best interests of the company's stockholders."
  • The lead candidate, dubbed TTX-MC138, is currently in the preclinical stage and is designed to treat metastatic cancers by inhibiting "microRNA-10b" to eliminate the metastasis.
  • TransCode believes that TTX-MC138 could be used as a treatment for many of these cancers, including breast, pancreatic, ovarian, colon, and glioblastomas.
  • Also see: TransCode Therapeutics Shares Shoot Higher After Encouraging Preclinical Data From Lead Cancer Candidate.
  • TransCode entered the stock market in July 2021, pricing its IPO at $4 a share and offering 6.25 million shares. However, it was planning to offer 2.8 million shares between $8-$10 a share.
  • Intrinsic Medicine and its blank-check partner Phoenix Biotech Acquisition Corp (NASDAQ:PBAX) terminated their reverse merger citing "current market conditions."
  • "After careful thought and consideration, we mutually determined that this action is in the best interest of all parties given current market conditions," stated Chris Ehrlich, CEO, and director of PBAX.
  • Price Action: RNAZ shares are up $112.8% at $0.90 on the last check Wednesday.
  • RNA生物技術轉碼治療公司納斯達克(Sequoia Capital：RNAZ)撤回了11月底提交給美國證券交易委員會的S-1檔案。
  • Transcode表示，撤回交易反映了Transcode的信念，即“目前的市場狀況不利於以符合公司股東最佳利益的條款進行發行。”
  • 主要候選藥物TTX-MC138目前處於臨床前階段，旨在通過抑制“microRNA-10b”消除轉移來治療轉移性癌症。
  • Transcode認為，TTX-MC138可以用於治療許多此類癌症，包括乳腺癌、胰腺癌、卵巢癌、結腸癌和膠質母細胞瘤。
  • 另請參閱： Transcode Treateutics股價飆升，此前領先的癌症候選人公佈了令人鼓舞的臨床前數據.
  • Transcode於2021年7月上市，IPO定價為每股4美元，發行625萬股。然而，該公司計劃發行280萬股股票，價格在8美元至10美元之間A股.
  • 內科醫學和它的空白支票合作夥伴鳳凰城 生物技術收購公司納斯達克(Sequoia Capital：PBAX)以“當前市場狀況”為由終止了反向合併。
  • PBAX首席執行官兼董事首席執行官克裡斯·埃爾利希表示：“經過深思熟慮，我們共同認為，鑑於目前的市場狀況，這一行動符合各方的最佳利益。”
  • 價格行動：在週三的最後一次檢查中，RNAZ股價上漲了112.8%，至0.9美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論